Vascular Endothelial Growth Factor A
"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
| Descriptor ID |
D042461
|
| MeSH Number(s) |
D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor A- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor-A
- VEGF-A
- Vasculotropin
- VEGF
- Vascular Endothelial Growth Factor
- Vascular Permeability Factor
- Permeability Factor, Vascular
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 7 | 7 | | 1999 | 0 | 2 | 2 | | 2000 | 0 | 4 | 4 | | 2001 | 0 | 6 | 6 | | 2002 | 0 | 10 | 10 | | 2003 | 5 | 8 | 13 | | 2004 | 2 | 12 | 14 | | 2005 | 11 | 5 | 16 | | 2006 | 5 | 10 | 15 | | 2007 | 7 | 11 | 18 | | 2008 | 11 | 10 | 21 | | 2009 | 8 | 21 | 29 | | 2010 | 8 | 12 | 20 | | 2011 | 5 | 13 | 18 | | 2012 | 6 | 13 | 19 | | 2013 | 6 | 18 | 24 | | 2014 | 8 | 7 | 15 | | 2015 | 4 | 8 | 12 | | 2016 | 6 | 6 | 12 | | 2017 | 2 | 7 | 9 | | 2018 | 6 | 9 | 15 | | 2019 | 0 | 8 | 8 | | 2020 | 7 | 4 | 11 | | 2021 | 0 | 9 | 9 | | 2022 | 3 | 12 | 15 | | 2023 | 0 | 14 | 14 | | 2024 | 4 | 3 | 7 | | 2025 | 0 | 1 | 1 | | 2026 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Caldwell AS, Patnaik J, Mehner L, McCourt E, Lynch A, Auer E, Mathias M, Oliver S, Jung J. Comparative outcomes for treatment of type 1 retinopathy of prematurity in a contemporary cohort. J AAPOS. 2026 Jun; 30(3):104847.
-
Blackman SA, Qerqez AN, Lee AG, Johnson NV, Owens JM, Lai GS, Aldrich EC, Sprenger KG, Lee J, Verrier S, Stoddart MJ, Nguyen AW, Maynard JA. Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. J Biol Chem. 2026 Jun; 302(6):111476.
-
Chang EI, Al-Juboori SI, Dear TB, Varanasi S, Painter CS, Stacey HE, Saunders EF, Stremming J, Louey S, Strode D, Dobrinskikh E, Jonker SS, Brown LD. Development of striated muscle microvasculature across the perinatal period in lambs. J Physiol. 2026 Apr; 604(8):3476-3493.
-
Smith CF, Ding KL, Seedorf GJ, Galambos C, Abman SH. Postnatally induced TBX4 insufficiency confers pulmonary hypertension and impairs lung development in infant mice. Pediatr Res. 2026 Feb; 99(2):791-797.
-
Swingle KL, Hamilton AG, Safford HC, Geisler HC, Thatte AS, Palanki R, Murray AM, Han EL, Mukalel AJ, Han X, Joseph RA, Ghalsasi AA, Alameh MG, Weissman D, Mitchell MJ. Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia. Nature. 2025 01; 637(8045):412-421.
-
Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, Xue K, Cehajic-Kapetanovic J, MacLaren RE, Charbel Issa P, Downes SM, De Silva SR. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye (Lond). 2024 Dec; 38(18):3569-3577.
-
Lisker-Cervantes A, Gill Z, Patnaik JL, Gnanaraj R, Lynch AM, Palestine AG, Mathias M, Manoharan N, Mandava N, de Carlo Forest TE. Association Between Systemic Levels of Vascular Endothelial Growth Factor and Optical Coherence Tomography Biomarkers in a Non-Neovascular Age-Related Macular Degeneration Cohort. Ophthalmic Surg Lasers Imaging Retina. 2025 01; 56(1):23-29.
-
Tunstead C, Volkova E, Dunbar H, Hawthorne IJ, Bell A, Crowe L, Masterson JC, Dos Santos CC, McNicholas B, Laffey JG, English K. The ARDS microenvironment enhances MSC-induced repair via VEGF in experimental acute lung inflammation. Mol Ther. 2024 10 02; 32(10):3422-3432.
-
Severyn NT, Esparza P, Gao H, Mickler EA, Albrecht ME, Fisher AJ, Yakubov B, Cook TG, Slaven JE, Walts AD, Tepper RS, Lahm T. Effect of estrogen receptor a on cardiopulmonary adaptation to chronic developmental hypoxia in a rat model. Am J Physiol Lung Cell Mol Physiol. 2024 06 01; 326(6):L786-L795.
-
Zhao G, Xue L, Weiner AI, Gong N, Adams-Tzivelekidis S, Wong J, Gentile ME, Nottingham AN, Basil MC, Lin SM, Niethamer TK, Diamond JM, Bermudez CA, Cantu E, Han X, Cao Y, Alameh MG, Weissman D, Morrisey EE, Mitchell MJ, Vaughan AE. TGF-ßR2 signaling coordinates pulmonary vascular repair after viral injury in mice and human tissue. Sci Transl Med. 2024 01 31; 16(732):eadg6229.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|